For the quarter ending 2025-09-30, CLDI had $785K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 |
|---|---|
| Amortization of debt discount and financing costs | 0 |
| Net loss | -16,004 |
| Depreciation and amortization expense | 1,228 |
| Stock-based compensation | 1,658 |
| Change in fair value of other liabilities and derivatives | 84 |
| Prepaid expenses and other current assets | 38 |
| Accounts payable | -924 |
| Accrued expenses and other current liabilities | -1,185 |
| Operating lease right of use liability | -1,068 |
| Net cash used in operating activities | -16,249 |
| Purchases of machinery and equipment | 91 |
| Net cash used in investing activities | -91 |
| Proceeds from exercise of common stock warrants | 0 |
| Proceeds from issuance of noncontrolling interest in nova cell | 0 |
| Related party proceeds from issuance of loan payable | 0 |
| Proceeds from issuance of convertible notes payable | 0 |
| Proceeds from issuance of common shares and warrants per subscription agreement | 0 |
| Proceeds from issuance of promissory note | 0 |
| Repayment of convertible note payable | 0 |
| Payment of debt issuance costs | 0 |
| Proceeds from public offerings | 12,663 |
| Proceeds from warrant inducement financing | 4,136 |
| Proceeds from registered direct offering | 3,503 |
| Proceeds from exercise of pre-funded warrants | 5 |
| Repayment of financing lease obligations | 63 |
| Repayment of principal on term notes payable | 200 |
| Repayment of principal on related party bridge loan payable | 200 |
| Payment of financing costs | 725 |
| Repayment of principal on related party term notes payable | 2,000 |
| Net cash provided by financing activities | 17,119 |
| Effect of exchange rate changes on cash | 6 |
| Net increase (decrease) in cash and restricted cash | 785 |
| Cash and cash equivalents at beginning of period | 9,809 |
| Cash and cash equivalents at end of period | 10,594 |
Calidi Biotherapeutics, Inc. (CLDI)
Calidi Biotherapeutics, Inc. (CLDI)